While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the ...
The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.
In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
Dr Philip Mease shares his clinical insights for diagnosing and treating fibromyalgia and psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results